254 related articles for article (PubMed ID: 8547743)
1. Medicine, pharmacy, and industry--a fly's eye view of health care.
Halperin JA
Ann Pharmacother; 1995 Sep; 29(9):925-33. PubMed ID: 8547743
[No Abstract] [Full Text] [Related]
2. Dissecting drug pricing: Supply chain, market, and nonmarket trends impacting clinical dermatology.
Nguyen HP; Go JA; Barbieri JS; Stough D; Stoff BK; Forman HP; Bolognia JL; Albrecht J;
J Am Acad Dermatol; 2020 Aug; 83(2):691-699. PubMed ID: 32330637
[No Abstract] [Full Text] [Related]
3. Assessment of the opportunities for pharmaceutical manufacturers in emerging markets.
Anderson T; Olson J; Sobelman D
J Manag Care Pharm; 2009 Jun; 15(5):396-402. PubMed ID: 19496636
[No Abstract] [Full Text] [Related]
4. A European perspective on regulation and technology.
Sharp J
PDA J Pharm Sci Technol; 1997; 51(3):104-10. PubMed ID: 9203822
[No Abstract] [Full Text] [Related]
5. Prescribing authority for pharmacists as viewed by organized pharmacy, organized medicine, and the pharmaceutical industry.
Segal R; Grines LL
Drug Intell Clin Pharm; 1988 Mar; 22(3):241-6. PubMed ID: 3366064
[TBL] [Abstract][Full Text] [Related]
6. Any willing provider meets the formulary.
Barrueta A
Health Syst Rev; 1995; 28(4):20, 22-3. PubMed ID: 10144359
[TBL] [Abstract][Full Text] [Related]
7. Proposal To Use VA Price As a Benchmark Is off the Mark.
Kirkner RM
Manag Care; 2016 Dec; 25(12):14-15. PubMed ID: 28121548
[TBL] [Abstract][Full Text] [Related]
8. Will lower drug prices jeopardize drug research? A policy fact sheet.
Light DW; Lexchin J
Am J Bioeth; 2004; 4(1):W1-4. PubMed ID: 15035915
[No Abstract] [Full Text] [Related]
9. The role of colleges of pharmacy in meeting the pharmacoeconomic needs of the pharmaceutical industry: a conference report.
Draugalis JR; Coons SJ
Clin Ther; 1994; 16(3):523-37; discussion 522. PubMed ID: 7923318
[TBL] [Abstract][Full Text] [Related]
10. The "Long" amendment.
Provost GP
Am J Hosp Pharm; 1967 Dec; 24(12):665. PubMed ID: 6073365
[No Abstract] [Full Text] [Related]
11. Forecasting the issues for managed care pharmacy.
Navarro RP
Am J Health Syst Pharm; 1998 Jan; 55(1):27-9. PubMed ID: 9437471
[No Abstract] [Full Text] [Related]
12. Update and evaluation of Australian guidelines. Government perspective.
Mitchell A
Med Care; 1996 Dec; 34(12 Suppl):DS216-25. PubMed ID: 8969329
[No Abstract] [Full Text] [Related]
13. What Was, Is No More: Community Pharmacy Economics.
Nightengale B
J Manag Care Spec Pharm; 2020 Jun; 26(6):703-705. PubMed ID: 32463771
[TBL] [Abstract][Full Text] [Related]
14. Globalization and pharmacy: a view from the developing world.
Matowe L; Katerere DR
Ann Pharmacother; 2002 May; 36(5):936-8. PubMed ID: 12014352
[No Abstract] [Full Text] [Related]
15. Evidence- or opinion-based pharmaceutical policy?
Lyles A
Clin Ther; 2004 Nov; 26(11):1922-3. PubMed ID: 15639703
[No Abstract] [Full Text] [Related]
16. Potential stifling effects of pharmaco-economics and regulatory policies.
Data JL
Am J Cardiol; 1998 Apr; 81(8A):34F-35F. PubMed ID: 9604904
[No Abstract] [Full Text] [Related]
17. Pharmacoeconomics: the new dismal science.
Luchins DJ
Adm Policy Ment Health; 2004 May; 31(5):425-7. PubMed ID: 15379388
[No Abstract] [Full Text] [Related]
18. Science, pharmacoeconomics and ethics in drug R&D: a sustainable future scenario?
Preziosi P
Nat Rev Drug Discov; 2004 Jun; 3(6):521-6. PubMed ID: 15173841
[No Abstract] [Full Text] [Related]
19. Pharmaceuticals and medical devices: FDA oversight.
Chaps NA
Issue Brief Health Policy Track Serv; 2009 Jan; ():1-28. PubMed ID: 19297718
[No Abstract] [Full Text] [Related]
20. Precipitating factors for pharmaceutical firms.
McCarthy R
State Health Care Am; 1997; ():39-43. PubMed ID: 10168083
[No Abstract] [Full Text] [Related]
[Next] [New Search]
